Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Reduced circulating NT-proANP concentration, Left atrial fibrosis, Left atrial enlargement, and Hypertension and others; and common findings: Atrial fibrillation and Atrial flutter. 8 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Heart and blood vessels | 6 | Left atrial fibrosis, Left atrial enlargement, Atrial fibrillation |
CORIN encodes corin, serine peptidase (1,042 aa). Serine-type endopeptidase involved in atrial natriuretic peptide (NPPA) and brain natriuretic peptide (NPPB) processing. Highest expression in Heart Atrial Appendage (27.7 TPM) and Heart Left Ventricle (10.0 TPM).
Cardiomyopathy, familial hypertrophic, 30, atrial is associated with mutations in the CORIN gene on chromosome 4.
The CORIN protein participates in CORIN(802-1042) hydrolyses NPPA to form NPPA(124-151) pathway.
CORIN is classified as a druggable target (Cell Surface, Druggable Genome, Enzyme, and Protease categories) with score 0.0.
Genetic testing for CORIN is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for cardiomyopathy, familial hypertrophic, 30, atrial has been reported in the published literature.
Phenotype severity distribution: 5 always present features, 2 common features.
No clinical trials have been registered for cardiomyopathy, familial hypertrophic, 30, atrial.
3 publications have been identified in PubMed for cardiomyopathy, familial hypertrophic, 30, atrial. Research spans Diagnostic / Biomarker (33%), Review / Meta-Analysis (33%), and Case Report / Case Series (33%).
Kopanos S (2025). [PMID: 40761432](https://pubmed.ncbi.nlm.nih.gov/40761432/). *Eur Heart J Case Rep*. [Case Report / Case Series]
Silajdzija E (2025). [PMID: 41195766](https://pubmed.ncbi.nlm.nih.gov/41195766/). *J Am Heart Assoc*. [Diagnostic / Biomarker]
Costabel JP (2025). [PMID: 40381755](https://pubmed.ncbi.nlm.nih.gov/40381755/). *Curr Probl Cardiol*. [Review / Meta-Analysis]
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 5:40 PM UTC
Online Mendelian Inheritance in Man
Common questions about cardiomyopathy, familial hypertrophic, 30, atrial
Brain and nerves |
1 |
Increased circulating brain natriuretic peptide concentration |
Lab test results | 1 | Increased circulating brain natriuretic peptide concentration |